



# Next Generation Antibody Platforms

Date        3<sup>rd</sup>- 4<sup>th</sup> December, 2018  
Venue      Taj Vivanta, Bengaluru, India





## Philip Tagari

Vice President  
Research, Amgen Inc.

Philip started his career as a scientist at Oxford and McGill Universities and joined Merck & Co. in 1987 where he contributed to several programs in eicosanoid and inflammatory biology, culminating in the discovery of odanacatib and rofecoxib, as well as the clinically active leukotriene D4 receptor antagonist MK-571 and the leukotriene biosynthesis inhibitor MK-591.

At Amgen, since 1998, he is currently responsible for biologics discovery, scaffold engineering, optimization and early manufacturability assessment; medicinal, oligonucleotide and peptide chemistry; protein conjugates (ADC, peptibodies) and reagents; assay development, screening, enzymological and pharmacological characterization and profiling (in vitro), as well as structural biology, biophysics, computational and analytical chemistry, materials logistics and automation.

Philip is a graduate of Gonville & Caius College, Cambridge University (UK).



## Prof. Sachdev Sidhu

Senior Investigator  
Ontario Institute for Cancer  
Research, University of Toronto

Dr Sachdev Sidhu currently teaches at the Department of Molecular Genetics and the Donnelly Centre at the University of Toronto. He is also the founder of Toronto Recombinant Antibody Centre (TRAC) and the Centre for Commercialization of Antibodies and Biologics (CCAB.)

He joined the Donnelly Centre for Cellular & Biomolecular Research in 2008 after 10 years as a Principal Investigator in the Department of Protein Engineering at Genentech. Dr Sidhu's research is primarily focused in the field of protein engineering and technologies that explore and shape protein and antibody structure and function, with the aim of crafting better therapies for cancer and other diseases.

Highly regarded for his extensive experience in commercial antibody discovery, Dr Sidhu has published more than 200 scientific papers and is a co-inventor on more than 50 patents granted or filed with the US patent office.

Dr Sidhu is a recipient of the 2015 Christian B. Anfinsen Award of the Protein Society for significant technological achievements in protein research.



## Prof. Sachdev Sidhu

Senior Investigator  
Ontario Institute for Cancer  
Research, University of Toronto

Dr Sachdev Sidhu currently teaches at the Department of Molecular Genetics and the Donnelly Centre at the University of Toronto. He is also the founder of Toronto Recombinant Antibody Centre (TRAC) and the Centre for Commercialization of Antibodies and Biologics (CCAB.)

He joined the Donnelly Centre for Cellular & Biomolecular Research in 2008 after 10 years as a Principal Investigator in the Department of Protein Engineering at Genentech. Dr Sidhu's research is primarily focused in the field of protein engineering and technologies that explore and shape protein and antibody structure and function, with the aim of crafting better therapies for cancer and other diseases.

Highly regarded for his extensive experience in commercial antibody discovery, Dr Sidhu has published more than 200 scientific papers and is a co-inventor on more than 50 patents granted or filed with the US patent office.

Dr Sidhu is a recipient of the 2015 Christian B. Anfinsen Award of the Protein Society for significant technological achievements in protein research.



## Ralf Guenther

Associate Director  
Protein Engineering and Antibody  
Merck KGaA

Ralf Guenther is the Associate Director- Department of Protein Engineering and Antibody Technologies at Merck KGaA in Darmstadt, Germany. He started as a bench scientist in target research, followed by a short episode on aptamer discovery.

Beginning 2013, Guenther heads the Merck-Syngene collaboration.



## Ralf Guenther

Associate Director  
Protein Engineering and Antibody  
Merck KGaA

Ralf Guenther is the Associate Director- Department of Protein Engineering and Antibody Technologies at Merck KGaA in Darmstadt, Germany. He started as a bench scientist in target research, followed by a short episode on aptamer discovery.

Beginning 2013, Guenther heads the Merck-Syngene collaboration.



## Abhishek Mathur

Biologics Externalization Director  
Amgen Inc.

Dr Abhishek Mathur is an accomplished industry leader with extensive experience in product development, CMC and Regulatory operations, and product commercialisation.

Dr Abhishek is regarded as a thoughtful scientific and operational leader specialising in Applied biology, Analytical Technologies, QbD and Biostatistics. He champions innovation in the analytical world and endorses newer technologies to improve operational efficiency and enhance data quality.

Dr Abhishek completed his BTech in Chemical Engineering from IIT Bombay (India) and PhD in Biological Sciences from Northwestern University (USA). He also holds Global MBA from Duke University (USA).





## Andreas Menrad

Vice President, Global Head  
NBE Technologies  
Merck KGaA

Andreas Menrad joined Merck from ALGETA ASA, where he served as their CSO. Earlier, he has held international senior positions at ABLYNX (CSO), GENZYME (General Manager and Vice President Antibody Therapeutics) and SCHERING AG, Berlin (Head of Antiangiogenesis Research Oncology). During his career in the pharmaceutical industry, Andreas progressed both NCE and NBE from bench to bedside.

He received his PhD from the University of Stuttgart and held a research position as a post-doctoral fellow at the Wistar Institute in Philadelphia, USA.



## Maloy Ghosh

CSO  
Zumutor Biologics Inc.

Dr Maloy Ghosh, an expert in the areas of cancer biology and biomarker development, is a member of the founding team at Zumutor Biologics. As CSO, Zumutor Biologics, he plays a crucial role in developing the company's technology platforms, R&D roadmap and product pipeline.

Currently, Maloy leads multiple R&D programs to create novel next-generation monoclonal antibody therapeutics through Zumutor's antibody platforms. These platform technologies are strategically used for Zumutor's Immuno-Oncology pipeline of products as well as in Partnered Innovation Engine (PIE) programs.

After his PhD from Bose Institute and IIT Kharagpur, he pursued post-doctoral research at Wright State University, Dayton and at Terry Fox Laboratory, Vancouver.

**Day 1: 3<sup>rd</sup> December 2018**

**8:00-9:00**  
Registration

**9:00-10:30**

Inauguration (lamp lighting, Abstarct book release, Introduction of the event, Kiran's message/talk and Jonathun talk)

**10:30-11:00**  
Tea Break

**11:00-11:40**

**Philip Tagari**

*The Past, Present & Future of Antibody-based Therapeutics*

**11:40-12:20**  
**Chadwick King**

*Addressing New Challenges in Therapeutic Antibody Discovery with Technology Innovation*

**12:30-13:30 pm**  
Lunch

**13:30-14:10**  
**Ralf Guenther**

*Transgenic Animals and Yeast Surface Display – a Versatile Combination for Selection and Engineering of Mono & Bispecific Antibodies*

**14:10-14:50**

**Maloy Ghosh**

*Human Antibody Library Development for Therapeutic Monoclonal Antibody Products*

**15:00-16:00**  
Tea Break + Poster Session

**16:00-16:40**

**Deepa Shankar**

*Nailing it with Thermo Fisher Scientific's antibody validation toolbox!*

**Day 2: 4<sup>th</sup> December 2018**

**8:30-9:10**

**Prof. Sachdev Sidhu**  
*From Systems Biology to Systems  
Biologics*

**9:10-10:00**

**Abhishek Mathur**  
*Impact of Monoclonal IgG Aggregates on  
In-Vitro Bioactivity Assessment*

**10:00-10:30**

Tea Break

**10:30-11:10**

**Andreas Menrad**  
*Therapeutic Antibodies: Current State  
and Future Trends*

**11:10-11:50**

**Dinakar Salunke**  
*New paradigms of antibody  
specificity at molecular level*

**11:50-12:30**

**Kevin Harvey**  
*Topic:*

**12:30-13:30**

Lunch

**13:30-14:10**

**Irina Rybina**  
*Topic:*

**14:10-14:50**

Syngene

**15:00-16:00**

Tea Break + Poster Session

**16:00-16:40**

Awards and closure ceremony  
of the symposium